Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. VistaGen Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2022 was -2,123.83%.
The historical rank and industry rank for VistaGen Therapeutics's ROC (Joel Greenblatt) % or its related term are showing as below:
VTGN'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -45308.29 Med: -5434.38 Max: -485.87
Current: -1404.07
During the past 13 years, VistaGen Therapeutics's highest ROC (Joel Greenblatt) % was -485.87%. The lowest was -45308.29%. And the median was -5434.38%.
VistaGen Therapeutics's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 36.80% per year.
VistaGen Therapeutics ROC (Joel Greenblatt) % Historical Data
The historical data trend for VistaGen Therapeutics's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
|
VistaGen Therapeutics Annual Data
|
|
Trend |
Mar13 |
Mar14 |
Mar15 |
Mar16 |
Mar17 |
Mar18 |
Mar19 |
Mar20 |
Mar21 |
Mar22 |
| ROC (Joel Greenblatt) % |
|
|
|
|
|
|
-5,630.36 |
-9,453.46 |
-1,011.99 |
-485.87 |
-1,433.56 |
|
VistaGen Therapeutics Quarterly Data
|
|
Jun17 |
Sep17 |
Dec17 |
Mar18 |
Jun18 |
Sep18 |
Dec18 |
Mar19 |
Jun19 |
Sep19 |
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
| ROC (Joel Greenblatt) % |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
-682.32 |
-860.71 |
-1,434.71 |
-1,251.19 |
-2,123.83 |
Competitive Comparison
For the Biotechnology subindustry, VistaGen Therapeutics's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
VistaGen Therapeutics ROC (Joel Greenblatt) % Distribution
For the Biotechnology industry and Healthcare sector, VistaGen Therapeutics's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where VistaGen Therapeutics's ROC (Joel Greenblatt) % falls into.
VistaGen Therapeutics ROC (Joel Greenblatt) % Calculation
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
| ROC (Joel Greenblatt) % | = | EBIT | / | Average of (Net fixed Assets | + | Net Working Capital) |
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
When net working capital is negative, 0 is used.
So ROC (Joel Greenblatt) % of VistaGen Therapeutics for the quarter that ended in Mar. 2022 can be restated as:
Note:
The EBIT data used here is four times the quarterly (Mar. 2022) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VistaGen Therapeutics Business Description
Traded in Other Exchanges
N/A
Address
343 Allerton Avenue, South San Francisco, CA, USA, 94080
VistaGen Therapeutics Inc is a biotechnology firm. The company is in its clinical stage and engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system. Its lead product candidate, AV-101, is an orally available prodrug candidate in Phase II development, initially for the adjunctive treatment of a major depressive disorder in patients with an inadequate response to standard antidepressants. The PH94B is a novel neuroactive nasal spray with therapeutic potential in a wide range of indications involving anxiety or phobia; PH10 is an odorless, fast-acting synthetic neurosteroid for neuropsychiatric indications involving depression.
Executives
| Saxe Jon S |
director |
FIRST HORIZON PHARMACEUTICAL CORP 660 HEMBREE PKWY STE 106 ROSWELL GA 30076 |
| Dotson Jerrold Duane |
officer: VP, CFO AND SECRETARY |
5 CENTERPOINTE DRIVE SUITE 400 LAKE OSWEGO OR 97035 |
| Singh Shawn |
director, officer: CHIEF EXECUTIVE OFFICER |
C/O VISTAGEN THERAPEUTICS, INC. 343 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080 |
| Snodgrass H. Ralph |
director, officer: PRES./CHIEF SCIENTIFIC OFFICER |
384 OYSTER POINT BLVD. SUITE 8 SOUTH SAN FRANCISCO CA 94080 |
| Smith Mark Alan |
officer: CHIEF MEDICAL OFFICER |
343 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080 |
| Mcpartland Mark A. |
officer: VP CORPORATE DEVELOPMENT |
C/O VISTAGEN THERAPEUTICS, INC. 343 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080 |
| Gin Jerry B |
director |
343 ALLERTON AVE SOUTH SAN FRANCISCO CA 94080 |
| Underdown Brian J. |
director |
C/O LUMIRA CAPITAL INVESTMENT MANAGEMENT 141 ADELAIDE ST. WEST, SUITE 770 TORONTO ONTARIO CANADA M5H 3L5 A6 00000 |
| Cunningham Ann Michelle |
director |
255 N CALDWELL CIRCLE DOWNINGTOWN PA 19335 |
| Rice A. Franklin |
officer: VP CORPORATE DEVELOPMENT |
384 OYSTER POINT BLVD. SUITE 8 SOUTH SAN FRANCISCO CA 94080 |
| Bonfiglio Gregory A. |
director |
384 OYSTER POINT BOULEVARD, NO. 8 SOUTH SAN FRANCISCO CA 94080 |
| Platinum Long Term Growth Vii, Llc |
10 percent owner |
152 WEST 57TH STREET 4TH FLOOR NEW YORK NY 10019 |
| Cato Holding Co |
10 percent owner |
4364 SOUTH ALSTON AVENUE DURHAM NC 27713 |
| Cato Allen Easley |
10 percent owner |
4364 SOUTH ALSTON AVENUE DURHAM NC 27713 |
| Jones Stephanie |
director, 10 percent owner, officer: PRESIDENT |
13834 W. HOYT ROAD RATHDRUM ID 83858 |
VistaGen Therapeutics Headlines
By tipranks.com 2022-02-13
By Seekingalpha 2021-01-24
By Seekingalpha 2022-02-10
By tipranks.com 2022-03-03
By Seekingalpha 2021-06-30
By Seekingalpha 2021-11-10
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
Personalize
Premium Gurus 
0.01(0.9%) Volume: 900,049 4:00PM EDT
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
NAS:VTGN has been successfully added to your 